With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

said Novo Nordisk A/' NVO semaglutide products, including Wegovy and Ozempic, are no longer in shortage. Semaglutide injection products were first added to the FDA's drug shortage list for Wegovy ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown for compounders to stop selling their versions of semaglutide. | Patients ...

Diving into the complexities of sustainability in healthcare packaging that include circular economy strategies, takeback ...

COPENHAGEN, Dec 5 (Reuters) - Danish drug maker Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of ...

After slashing the U.S. prices of several of its insulin products by 75% at the start of 2024, Novo Nordisk is ending the ... Novo will drop its U.S. list price for its Fiasp by 75% and for ...

Novo's nomination of semaglutide ... criteria it will use in evaluating whether drug products or categories of drug products belong on a DDC list. FDA proposes to consider these criteria ...

Pharmaceutical manufacturer Novo Nordisk ... drug shortage list, compounding pharmacies were able to sell copycat versions of semaglutide at a significantly reduced price. These products were ...